GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo
Pozen is counting on safety data from two GSK Phase IIIb trials completed after the migraine therapy’s filing to satisfy FDA’s “approvable” letter.
Pozen is counting on safety data from two GSK Phase IIIb trials completed after the migraine therapy’s filing to satisfy FDA’s “approvable” letter.